Thursday, March 28, 2024
Advertisement
  1. You Are At:
  2. News
  3. Business
  4. Cadila launches first cheaper copy of world's top-selling drug

Cadila launches first cheaper copy of world's top-selling drug

Mumbai: Drugmaker Cadila Healthcare Ltd has launched in India the first bio similar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its US price. The drug's branded version is

India TV Business Desk India TV Business Desk Updated on: December 10, 2014 10:24 IST
cadila launches first cheaper copy of world s top selling
cadila launches first cheaper copy of world s top selling drug

Mumbai: Drugmaker Cadila Healthcare Ltd has launched in India the first bio similar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its US price. The drug's branded version is sold under the name Humira by U.S. firm AbbVie Inc, and costs $1,000 for a vial in the United States.

Humira had sales of $3.26 billion in the quarter ended September, accounting for 65 percent of AbbVie's total revenue.

The company will launch its version under the name Exemptia. The drug will help millions of patients suffering from rheumatoid arthritis rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and other auto immune disorders.

Biosimilars are cheaper copies of biotech drugs - medicines made from proteins and other large molecules.

The company expects sales between Rs 1-2 billion from its biosimilar of Humira in the Indian market.

Zydus Cadila currently employs over 16,000 people across the world and is targeting to achieve sales of over Rs 10,000 crore by 2015.

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from Business

Advertisement
Advertisement
Advertisement
Advertisement